AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: arnie h who wrote (1125)	2/21/1998 1:10:00 AM
From: D.Right	Read Replies (3) of 2173

Dear Arnie: Back to your question about the same 75% stay on pramlintide in both type I and II. There is a big news splash about the new rat hormone gene cloned, orexin, for controlling appetite. While it should generate some excitement, but any medicine that can come out of it, if ever, will be at least a decade away. At the meantime, people who need treatment the most to control their obesity are many of the type II diabetes patients. Pramlintide has shown it can cause statistic significant weight loss in two different doses in the last clinical III, I believe that indication alone will give AMLN a market in type II no smaller than the whole type I market. Of course, they have to have pramlintide approved for type II first. The 75% just showed that even it is approved with some condition attached for type II, those patients who want it will get it. The only worry we should have is FDA, no need to worry about the market at all. If there is any sign in the coming trials that AMLN will get type II OKed, I will hold my shares for a long long time. Good weekend. D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next